Strike Pharma is using its proprietary technology for targeted nanoparticle delivery to enable in vivo CAR-T therapy. The lead candidate, STR3/19, is based on a lipid nanoparticle that carries mRNA for an anti-CD19 CAR that is selectively delivered to T cells via an anti-CD3 antibody. This is an off-the-shelf alternative to current CAR-T therapies, that reprogrammes T cells to B-cell depleting CAR-Ts inside the body and that is intended for treatment of B-cell dependent autoimmune disease, such as SLE, and for B-cell lymphoma. Strike Pharma was founded in 2020, has Eir Ventures and Flerie Invest as major shareholders, and is headquartered at Smile Venture Hub, Medicon Village, Lund, Sweden.
| Employees | 19 (9 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
Looking for a particular Strike Pharma AB employee's phone or email?
Strike Pharma AB Questions
Per Norlén is the CEO of Strike Pharma AB.
9 people are employed at Strike Pharma AB.
Top Strike Pharma AB Employees
-
1
-
1
-
Safia Guleed
Scientist at Strike Pharma AB
Copenhagen, DK
